Establishment of a reference formulation for bioequivalence assessment of rifampicin-containing FDCs: An essential step towards improving tuberculosis treatment

International Journal of Tuberculosis and Lung Disease

Volumn 9, Issue 7, 2005, Pages 791-796

  Ashokraj, Y ^a   Singh, I ^a   Kaur, K J ^a   Kohli, G ^a   Bhade, S R ^a   Varma, M V S ^a   Kaul, C L ^a   Panchagnula, Ramesh ^a  

^a NATIONAL INSTITUTE OF PHARMACEUTICAL EDUCATION AND RESEARCH NIPER   (India)

Author keywords

Bioequivalence; DOTS; Fixed dose combinations; Rifampicin; Tuberculosis

Indexed keywords

AKURIT 3; ETHAMBUTOL; ETHAMBUTOL PLUS ISONIAZID PLUS RIFAMPICIN; ISONIAZID; RIFAMPICIN; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BLOOD LEVEL; DRUG FORMULATION; FEASIBILITY STUDY; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MALE; NORMAL HUMAN; OPEN STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STANDARD; TUBERCULOSIS; WORLD HEALTH ORGANIZATION;

ANTIBIOTICS, ANTITUBERCULAR; ANTITUBERCULAR AGENTS; AREA UNDER CURVE; CROSS-OVER STUDIES; DRUG THERAPY, COMBINATION; ETHAMBUTOL; HUMANS; ISONIAZID; RIFAMPIN; THERAPEUTIC EQUIVALENCY; TUBERCULOSIS;

EID: 23744436813     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Blomberg B, Fourie B. Fixed-dose combination drugs for tuberculosis: application in standardized treatment regimens. Drugs 2003; 63: 535-553.
2. Anonymous. The promise and reality of fixed-dose combinations with rifampicin. A joint statement of the International Union Against Tuberculosis and Lung Disease and the Tuberculosis Programme of World Health Organization. Tubercle Lung Dis 1994; 75: 180-181.
3. Agrawal S, Singh I, Kaur K J, Bhade S R, Kaul C L, Panchagnula R. Comparative bioavailability of rifampicin, isoniazid and pyrazinamide in a four drug fixed dose combination with separate formulations at the same dose levels. Int J Pharm 2004; 276: 41-49.
4. Agrawal S, Kaur K, Singh I, Bhade S R, Kaul C L, Panchagnula R. Assessment of bioequivalence of rifampicin, isoniazid and pyrazinamide in a four drug fixed dose combination with separate formulations at same dose level. Int J Pharm 2002; 233: 169-177.
5. Panchagnula R, Kaur K, Singh I, Kaul C L. The WHO Simplified Study Protocol in Practice: the investigation of Combined Formulation supplied by WHO. Int J Tuber Lung Dis 1999; 3 (Suppl 3): S336-S342.
6. Agrawal S, Singh I, Kaur K J, Bhade S R, Kaul C L, Panchagnula R. Bioequivalence trials of rifampicin containing formulations: extrinsic and intrinsic factors in the absorption of rifampicin. Pharmacol Res 2004; 50: 317-327.
7. United States Pharmacopoeia. USP 26. Rifampicin, isoniazid, pyrazinamide and ethambutol hydrochloride tablets. Rockville, MD: United States Pharmacopoeia Convention, Inc, 2003: pp 1645-1646.
8. Ashokraj Y, Agrawal S, Varma M V S, et al. Quality control of anti-tuberculosis fixed dose combination formulations in global market: An in vitro study. Int J Tuberc Lung Dis 2004; 8: 1081-1088.
9. Panchagnula R, Sood A, Sharda N, Kaur K, Kaul C L. Determination of rifampicin and its main metabolite in presence of pyrazinamide and isoniazid in plasma and urine samples by HPLC method. J Pharm Biomed Analysis 1999; 18: 1013-1020.
10. Hauschke D, Steinijans V W, Diletti E A. Distribution free procedure for the statistical analysis of bioequivalence studies. Int J Clin Pharmacol Ther Toxicol 1990; 28: 72-78.
11. Fourie B, Pillai G, McIlleron H, et al. Establishing the bioequivalence of rifampicin in fixed dose formulations containing isoniazid with or without pyrazinamide and/or ethambutol compared to single drug reference preparations administered in loose combination (Model Protocol). WHO/CDS/TB/99.274. Geneva, Switzerland: WHO, 1999.
12. Agrawal S, Panchagnula R. Dissolution test as a surrogate for quality evaluation of rifampicin containing fixed dose combination formulations. Int J Pharm 2004; 287: 97-112.
13. Panchagnula R, Agrawal S. Biopharmaceutic and pharmacokinetic aspects of variable bioavailability of rifampicin. Int J Pharm 2004; 271: 1-4.
14. United States Food and Drug Administration (FDA), Center for Drug Evaluation and Research (CDER). Guidance for industry. Bioavailability and bioequivalence studies for orally administered products-general considerations. Rockville, MD: FDA, March 2003.
15. The European Agency for the Evaluation of Medicinal Products (EMEA). Evaluations of Medicines for Human Use. Committee for Proprietary Medicinal Products (CPMP): Note for guidance on the investigation of bioavailability and bioequivalence. CPMP/EWP/QWP/1401/98. London, UK: EMEA, July 2001.
16. Pillai G, Fourie P B, Padayatchi N, et al. Recent bioequivalence studies on fixed dose combination anti-tuberculosis drug formulations available on the global market. Int J Tuberc Lung Dis 1999; 3 (Suppl 3): S309-S316.
17. McIlleron H, Wash P, Burger A, et al. Widespread distribution of a single drug rifampicin formulation of inferior bioavailability in South Africa. Int J Tuberc Lung Dis 2002; 6: 356-361.
18. Background document for the conference on 'Fixed dose combinations drug products: Scientific and technical issues related to safety, quality and effectiveness'. Gaborone, Botswana: US department of Health and Human Services, March 29-30, 2004. www.globalhealth.gov/fdc.shtml